Bruce Strober, MD, PhD
Dr Strober, an expert in psoriasis, provides 10 clinical pearls from the psoriasis presentations presented at MauiDerm 2014.
- Psoriasis is associated with chronic kidney disease.
- Psoriasis is associated with 5-yr reduced life-expectancy.
- Psoriasis is more highly associated with diabetes risk than is rheumatoid arthritis.
- IL-17 inhibition is associated with very high efficacy.
- Ustekinumab is an IL-12/23 inhibitor that has some efficacy in psoriatic arthritis, but not as high an efficacy that is displayed by TNF-inhibitors.
- Apremilast is a PDE4 inhibitor that has efficacy in both psoriasis and psoriatic arthritis.
- Calcipotriene and calcitriol when used in combination with topical corticosteroids may reduce the risk of cutaneous atrophy.
- Topical corticosteroids only rarely induce adrenal suppression, even if used on areas of high percutaneous absorption.
- Psoriatic arthritis is present in 20-30% of psoriasis patients.
- Concomitant methotrexate reduces the immunogenicity and augments the efficacy of biologic therapies for psoriasis.